The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Markets Update: How ESG is Changing
How Are Small Businesses Surviving?
Markets Update: Latin America
Client Call: How Retailers Will Re-Open
Markets Update: Central Bank Responses
Client Call: CFO Perspectives
Markets Update: Oil Prices Drop to Record Lows
Client Call: Oil Update as Negative Prices Emerge
How the Housing Sector Has Been Impacted by the Economic Slowdown
Markets Update: What Investors Are Watching
How Markets Have “Changed Forever”
Markets Update: CEO David Solomon Shares His Perspectives on the Current Environment
COVID-19’s Impact on US Small Businesses
Markets Update: Do Investors Think the S&P 500 Has Bottomed Out?
Client Call: Market Volatility and Potential Economic Impacts
Markets Update: Europe and COVID-19
Update on US Growth and Earnings Forecasts, and Expected Stimulus Programs
Markets Update: How COVID-19 Is and Isn't Like the '08 Financial Crisis
Re-thinking How We Work During a Pandemic
Markets Update: The Fed's Recent Efforts to Increase Liquidity
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money